Juliann Chmielecki, Ph.D.
Affiliations: | 2011 | Weill Cornell Medical College, New York, NY, United States |
Area:
Oncology, Molecular Biology, BiochemistryGoogle:
"Juliann Chmielecki"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| William Pao | grad student | 2011 | Weill Cornell Medical College | |
| (Identification and functional characterization of aberrant tyrosine kinases in cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Johnson M, Serra Traynor C, Vishwanathan K, et al. (2023) Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer. Clinical Pharmacology and Therapeutics |
| Gray JE, Han JY, Telaranta-Keerie A, et al. (2023) Pan-tumor analytical validation and osimertinib clinical validation in EGFR mutant non-small cell lung cancer, supporting the first next generation sequencing liquid biopsy in vitro diagnostic. The Journal of Molecular Diagnostics : Jmd |
| Gray JE, Ahn MJ, Oxnard GR, et al. (2023) Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Chmielecki J, Gray JE, Cheng Y, et al. (2023) Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14: 3179 |
| Chmielecki J, Mok T, Wu YL, et al. (2023) Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature Communications. 14: 1071 |
| Chmielecki J, Gray JE, Cheng Y, et al. (2023) Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14: 1070 |
| Yu HA, Goldberg SB, Le X, et al. (2021) Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clinical Lung Cancer |
| Vaclova T, Grazini U, Ward L, et al. (2021) Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature Communications. 12: 1780 |
| Smith HW, Yang L, Ling C, et al. (2020) An ErbB2 splice variant lacking exon 16 drives lung carcinoma. Proceedings of the National Academy of Sciences of the United States of America |
| Gray JE, Han J, Telaranta-Keerie A, et al. (2020) Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib. Journal of Clinical Oncology. 38: 9553-9553 |